profit from every $100 of sales.
$0$100
HUTCHMED (China)
$14.90+0.34% today
-1.8% in 1 year
1-year low $9.991-year high $16.05
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $5.67 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What HUTCHMED (China) sold, what it kept, and what it did with the cash.
Sales went from $426 million in 2022 to $549 million in 2025, with $457 million of profit last year.
SalesProfit
HUTCHMED (China) vs. similar companies
HUTCHMED (China) grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| HUTCHMED (China) | 5.7× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads HUTCHMED (China)'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 426 | 838 | 630 | 549 | |
| 115 | 454 | 281 | 212 | |
| -406 | 22 | -41 | -36 | |
| -401 | 67 | 14 | 515 | |
| -361 | 101 | 38 | 457 | |
| -2.15 | 0.60 | 0.20 | 2.65 | |
| 27.0% | 54.1% | 44.6% | 38.7% | |
| -95.3% | 2.6% | -6.4% | -6.5% | |
| -84.6% | 12.0% | 6.0% | 83.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,029 | 1,280 | 1,274 | 1,753 |
| Cash | 313 | 284 | 154 | 71 |
| Total debt | 27 | 86 | 90 | 98 |
| Total liabilities | 393 | 536 | 502 | 502 |
| 610 | 731 | 760 | 1,238 | |
| 169 | 174 | 175 | 175 | |
| -50.8% | 5.7% | 0.2% | 29.7% | |
| -59.1% | 13.8% | 5.0% | 36.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -269 | 219 | 0 | -65 | |
| 37 | 33 | 18 | 24 | |
| -305 | 187 | -17 | -89 | |
| Dividends paid | – | – | – | – |
| 48 | 9 | 36 | 0 | |
| 31 | 37 | 22 | 15 |
Valuation
- 5.7×
- 46.6×
- –
- 1.8×
- 4.7×
- –
- 5.1×
- -3.4%
- 17.6%
- 0.0%
Profitability
- 38.7%
- -6.5%
- 83.3%
- -4.7%
- 30.4%
- -3.9%
- 37.0%
- 26.1%
- -2.7%
- 28.2%
Growth
- +8.8%
- –
- −353.2%
- –
- +1.0%
Financial health
- 0.1×
- 0.08
- 5.6%
- 175.1×
- 4.96
- 4.83
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 3%of 946
Bottom 17%of 872
Top 3%of 563
Bottom 41%of 868
Bottom 24%of 986
What analysts expect
- Average price target
- $17.50
- Range
- $17.50 – $17.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Aug 7, 2025 | 1.30 | 1.46 | −11.0% |
| Jul 2, 2025 | 1.30 | – | – |
| Mar 19, 2025 | 0.03 | -0.09 | +137.9% |
| Sep 30, 2024 | 0.03 | – | – |
| Jul 31, 2024 | 0.01 | – | – |
| Jun 10, 2024 | 0.07 | – | – |
| Feb 28, 2024 | -0.04 | -1.08 | +96.3% |
| Jul 31, 2023 | 0.10 | – | – |
News
Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCMSeeking Alpha · Aug 28, 2026The newest story we have is from Aug 28, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
75Pass
Philip Fisher
47No pass
Peter Lynch
75Pass
Joel Greenblatt
86Pass
Charlie Munger
59No pass
Terry Smith
49No pass
Questions about HUTCHMED (China)
Is HUTCHMED (China) a good stock to buy?
A strong, very profitable business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the HUTCHMED (China) AI analysis
What does HUTCHMED (China) do?
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does HUTCHMED (China) pay a dividend?
No. HUTCHMED (China) does not pay a dividend at the moment.
Is HUTCHMED (China) stock halal?
Questionable. HUTCHMED (China) sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has HUTCHMED (China) stock done over the past year?
Down 1.8% over the past twelve months, to $14.90. It traded between $9.99 and $16.05 and is 7.2% below its high.
Who are HUTCHMED (China)'s competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with HUTCHMED (China)'s.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.